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Abstract
Aims—Our studies have shown that the association between integrin-associated protein (IAP)
and SHPS-1 regulates the response of cells including osteoclasts, osteoblasts, smooth muscle and
retinal endothelial cells to Insulin-like growth factor-I (IGF-I). The aims of this study were to
determine whether the regulation of IGF-I responsiveness by IAP/SHPS-1 association is a
generalized response of endothelial cells, to identify the mechanism by which IAP/SHPS-1
association contributes to changes in endothelial cell responses to IGF-I and to determine whether
inhibiting their association alters pathophysiologic changes that occur in vivo.
Methods and Results—Endothelial cells, maintained in 5mmol/l glucose, showed constitutive
cleavage of the extracellular domain of IAP (containing the SHPS-1 binding site) and IAP/SHPS-1
association was not detected. In contrast, hyperglycemia inhibited IAP cleavage allowing IAP/
SHPS-1 association and IGF-I stimulated SHPS-1 tyrosine phosphorylation. Exposure to an anti-
IAP antibody that disrupts IAP/SHPS-1 association inhibited IGF-I stimulated tube formation and
increased permeability. Rodent models of endothelial cell dysfunction were used to investigate the
role of IAP-SHPS-1 association in endothelial cell function in vivo. Basal IAP/SHPS-1 association
was not detected in retinal extracts in normal rats but was fully restored in rats with diabetes. The
anti-IAP antibody inhibited IAP/SHPS-1 association and reduced retinal vascular permeability and
leukocyte adherence to levels that were similar to non-diabetic rats. The antibody also
significantly inhibited aberrant neovascularization that was induced by hypoxia.
Conclusions—Our results demonstrate that the increase in IAP/SHPS-1 association contributes
to the pathophysiologic changes in the endothelium that are induced by hyperglycemia and
hypoxia.
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Changes in endothelial cell function in response to hyperglycemia include increased
vascular permeability and increased leukostasis, as well as increased cellular proliferation
leading to new blood vessel formation. Enhanced responsiveness of vascular cells to IGF-I
has been implicated in all these vascular responses to hyperglycemia. Hypophysectomy
decreases serum IGF-I concentrations and arrests retinopathy progression [1]. IGF-I levels
in vitreous correlate with the presence of proliferative retinopathy [2] and administration of
somatostatin analogs which decrease IGF-I levels in vitreous ameliorates retinopathy
progression [3]. Mice that over express IGF-I in the retina develop changes associated with
diabetic retinopathy, including increased capillary permeability and angiogenesis [4].
The biological responses of smooth muscle and retinal endothelial cells (RECs) to IGF-I are
enhanced when cells are cultured in hyperglycemic conditions [5,6]. This response is
dependent upon hyperglycemia-facilitated association of two cell surface proteins, integrin
associated protein (IAP or CD47) and SHPS-1 [5,7,8]. The aims of this current study were
1) to determine whether the regulation of IGF-I responsiveness by IAP/SHPS-1 association
is a generalized response of endothelial cells to hyperglycemia conditions, 2) to identify the
mechanisms by which the association between IAP and SHPS-1 contributes to
hyperglycemia-mediated changes in endothelial cell responses to IGF-I and 3) to determine




Primary HUVECs (Lonza) were grown in M-199 (Life Technologies) plus EGM-2
Endothelial Cell Growth Medium supplements (Lonza, Walkersville MD) containing 5
mmol/l glucose. HUVECs were switched to growth medium containing 15 mmol/l glucose
for 3 days. 10 mmol/l mannitol was added to the medium containing 5 mmol/l to control for
the difference in osmolarity. Cultures were quiesced for 14 hr in serum-free (SF) M-199
containing 5 or 15 mmol/l glucose and exposed to IGF-I (50 ng/ml) (Genentech, San
Fransisco, CA), the monoclonal anti IAP antibody, B6H12 (1 μg/ml) as described
previously [8]) or the VEGF inhibitor Je-11 (10 μg/ml) (EMD Biosciences, Rockland, MA).
RECs were grown as we have described previously [5]. Use of human cells was approved by
the University of North Carolina Ethics Committee.
Cell lysis, immunoprecipitation and immunoblotting
Lysates were immunoprecipitated, separated by SDS-PAGE and transferred to Immobilon
filters (Millipore, Billerica, MA) prior to immunoblotting to visualize proteins [5].
Antibodies used for immunoblotting were anti-phosphotyrosine (PY99, Santa Cruz, Santa
Cruz, CA), anti-SHPS-1 (BD Biosciences, Franklin Lakes, NC), anti-occludin (Invitrogen,
Carlsbad, CA) and anti-VEGF R2 (R and D Systems, Minneapolis, MN).
Real-time PCR analysis of VEGF mRNA
Total RNA was harvested using the Qiagen RNAeasy kit. cDNA was made using 1 μg of
RNA and High Capacity cDNA Reverse Transcription Kit (Life Technologies, Grand Island,
NY). Real-Time PCR reactions were set up using the TaqMan Gene Assay kit and (ABI
Catalog number: for VEGFA Hs0090005_ ml and GAPDH Hs 999999905_ml) primer probe
sets. Reactions were performed in quadruplicate. ABI SDS 2.2.2 software was used to
determine relative amounts of RNA.
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In vitro permeability assay
HUVECs were plated in growth medium (15 mmol/l glucose) on collagen coated Transwell
inserts (24 well) After 24 hrs medium was changed to SFM-199 (15 mmol/l glucose)
containing IGF-I (50 ng/ml) plus B6H12 (1 μg/ml). After 14 hr fluorescently labeled
dextran (average MW 70K) was added (Sigma, St Louis, MO) (0.5 mg/ml). After 1 hr
medium was collected from the lower chamber and the amount of FITC-dextran was
measured in a fluorescence detecting microplate reader (Fluor Imager 595 Molecular
Dynamics) (excitation and emission wave lengths 294 and 521 nm).
In vitro tube formation assay
HUVECs maintained in 15 mmol/l glucose were switched to SFM-199 containing IGF-I (50
ng/ml), B6H12 (1 μg/ml) for 14 hr. They were then plated on 24 well plates coated with 500
μl of growth factor reduced matrigel (BD Biosciences) (1.5 × 105 cells/ml/well). After 4
hours the plates were photographed at 10 x and the number of tubes/cm2 area in 6 random
areas of each well was determined [9]. One tube is the area between two branch points
(shown in figure 2 as the area between two “x” on the image).
In vitro measurement of leukocyte adhesion
RECS were plated in 96 well plates (3 × 104 cells/100μl/well) in growth medium (15 mmol/
l glucose). After 48–72 hrs SFM-199 (15 mmol/l glucose) was added for 4 hours, +/− TNFα
(Life Technologies; 30 ng/ml) for 2 hours. The monolayer was rinsed 3x then 100 μl of
labeled leukocytes added. The monolayers were rinsed 3x and then 100 μl/ml of SFM-199
was added prior to visualization with fluorescent microscope (Excitation and emission wave
length 485 and 530 nm respectively). Adherent, fluorescent leukocytes were counted.
Preparation of HL-60 leukocytes
1 × 106 leukocytes were incubated with 1 μg/ml Calcein-AM (BD Biosciences) in SFM-199
(15 mm/l glucose) (37°C for 1 hour). The labeled cells were then loaded on to the REC
monolayer (100 μl/well). 500 μl of SFM-199 was added to the lower chamber.
Animals for diabetes study
Male Sprague–Dawley rats (Charles River, Wilmington, MA) were housed under 12-h:12-h
light–dark conditions and received food and water ad libitum. All protocols were approved
by the University of North Carolina at Chapel Hill Animal Care and Use Committee and
adhere to the National Institutes of Health guidelines and the Association for Research in
Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Visual
Research.
Diabetes induction protocol
Control rats received an injection of vehicle. Streptozotocin (STZ) was given by
intraperitoneal injection (50 mg kg −1). Hyperglycemia was confirmed 6 days later. At that
point insulin injections were commenced (Neutral Protamine Hagedorn Insulin 9U kg−1/
day). 20 days post-injection, 10 animals in the STZ group received an injection of control,
mouse IgG (50 μg kg−1) and 10 received an injection of B6H12 (50 μg kg−1) every 72 hours
for 30 days. Further details are given in Table 1.
In vivo measurement of vascular permeability [10]
Rats were injected with Nembutal (80 mg kg−1) (Southern Anesthesia, West Columbia, SC).
Once deep anesthesia had been achieved warmed Evans blue (45 mg kg−1) (Fisher
Scientific, Pittsburgh, PA) was injected into the tail vein. Evans Blue dye binds to albumin
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allowing the measurement of albumin leakage from the vasculature [10]. After 2 hrs a lethal
dose of anesthetic (100 mg kg−1) was administered. Blood was collected and centrifuged at
12,000 × g for 5 min. The rats were perfused with 1% paraformaldehyde in citrate then the
eyes removed and placed in PBS. The retinas were removed, lyophilized then resuspended
in formamide and incubated at 70°C. After 18 the retina/formamide was centrifuged at
13,000 × g for 10 min.
A standard curve was generated using serial dilutions of Evans Blue (30 mg/μl). The
absorbance was measured using a Nanodrop spectrophotometer (Thermo-Scientific,
Rockford, IL) with excitation and emission wavelengths of 620 and 740 nm. The amount of
Evans Blue permeation from each retina was calculated using the following: [Evans Blue
(μg)/retina dry weight (g)]/[time − averaged Evans Blue concentration (μg)/plasma (μl) ×
circulation (h)].
In vivo measurement of leukocyte adhesion
Rats were anesthetized with Nembutal as above. The chest cavity was opened and a 19
gauge needle was inserted into the left ventricle and infused with PBS (300ml/kg) followed
with 1% paraformaldehyde (100ml kg−1), 1 % (wt/vol) bovine serum albumin in PBS (20ml
kg−1), Concanavalin A FITC (Vector Labs, Burlingame, CA) at a concentration of 40mg/ml
in PBS (5 ml kg−1) and finally with PBS (20ml kg−1). Blood was collected and the eyes
were removed and placed in paraformaldehyde. After 2 hrs the eyes were rinsed twice in
PBS. Retinas were isolated, the hyaloidal vessels and vitreous removed with ora serratas
intact. By making 4 incisions 90° apart, the retinas were flattened and then mounted onto
microscope slides.
Analysis of retinal homogenates
Retina were removed from the eye and then frozen in modified radioimmunoprecipitation
assay buffer with a protease inhibitor cocktail (HALT; Thermoscientific) then analyzed by
immunoblotting [5].
Rodent model of retinopathy of prematurity (ROP)
On post natal day (p) 0, litters of 12 to 14 newborn Sprague-Dawley rat pups with their
mothers (Charles River) were placed into an incubator (OxyCycler; BioSpherix, New York,
New York) and inspired oxygen cycled between 50 % and 10 % every 24 hours. At p12 rat
pups were given an intraperitoneal injection of B6H12 (20μg/pup) or control IgG daily for 6
days. After 7 cycles of oxygen fluctuations at p14, pups were placed into room air for 4
days. Oxygen and carbon dioxide levels were monitored daily [11].
Following sacrifice at p18, eyes were fixed in paraformaldehyde, 2 % (wt/vol). Retinas were
isolated with ora serratas intact and were placed into PBS. Four incisions 90° apart were
made, the retinas were flattened and mounted onto slides [12].
To stain the vasculature, the flattened retinas were permeabilized in 70 % ethanol and then
PBS, 1% (vol/vol) Triton X-100. They were incubated with Alexa Fluor 568-conjugated
Griffonia simplicifolia (Bandeiraea) isolectin B4 (5 μg/ml) (Invitrogen, Carlsbad, CA) [13].
Images of the retinal blood vessels were captured using a Nikon 80i Research Upright
Microscope with Surveyor/TurboScan software (Nikon Inc) and were digitally stored for
analysis.
Total retinal area, summed peripheral avascular retinal area, and areas of IVNV were
computed in pixels using Image Tool v.3 (The University of Texas, San Antonio) and were
converted to square millimeters (using a calibration bar). The IVNV was defined as
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neovascularization growing into the vitreous at the junction of vascular and avascular retina
[14]. For clock hours, flat mounts were divided into 12 clock hours of equal area using
Adobe Photoshop (Adobe Systems Inc) and the number of clock hours (0–12) exhibiting
IVNV was determined [15,16]. Areas of neovascularization were measured, summed, and
expressed as a percentage of total retinal area. Measurements were performed by 2
independent masked reviewers.
Protein estimation
The protein concentration of lysates was determined using a BCA protein assay kit
(Thermoscientific).
Statistical Analysis
Chemiluminescent images were obtained from autoradiographs (Thermoscientific) and
analyzed as described [5]. The Student’s t test was used to compare differences between
treatments. The results that are shown are representative of at least three independent
experiments.
Results
Regulation of IAP association with SHPS-1in vitro
To determine whether the hyperglycemia induced increase in IAP/SHPS-1 association was a
more generalized response of endothelial cells to glucose we examined IAP/SHPS-1
association in HUVEC cells. Consistent with our previous observations in REC [5] we
determined that there was a significant, 5 ± 0.9 fold increase in IAP association with
SHPS-1 when HUVECs were cultured in 15 compared with 5 mmol/l glucose [fig 1a (mean
± SEM, n = 3)]. This was associated with a 24 ± 7 fold increase in SHPS-1 phosphorylation
in response to IGF-I (Fig 1b mean ± SEM, n = 3) comparable to our previous data in RECs
[5]. The lack of IAP/SHPS-1 association in vascular smooth muscle cells maintained in 5
mmol/l glucose is due to cleavage of the extraceullar domain of IAP, the region of IAP that
contains the SHPS-1 binding site [7]. Immunoblotting of lysates from HUVEC and REC
with the anti-IAP antibody (B6H12), which detects both intact IAP and the residual
membrane-associated fragment that is present after cleavage, revealed degradation of IAP in
5 mmol/l glucose (Fig 1c).
Disruption in IAP and SHPS-1 association blocks IGF-I stimulated increases in endothelial
cell permeability
We next determined if the glucose mediated increase in IAP/SHPS-1 association played a
role in the regulation of endothelial permeability in response to hyperglycemia and IGF-I.
IGF-I stimulated a significant 2.4 ± 0.14 (mean ± SEM n = 3 p <0.01) increase in the
amount of dextran that permeated the HUVEC monolayer in 1 hour. However when cells
were incubated with B6H12 which disrupted IAP/SHPS-1 there was no significant increase
in dextran permeation compared with control (Fig 2a).
A decrease in the junction protein occludin has been implicated in vascular permeability in
diabetes. In both HUVECs and RECs cultured in 15 mmol/l glucose IGF-I stimulated a
significant decrease in occludin levels (a 5.3 ± 1.2 and 7.5 ± 1.9 fold decrease respectively;
mean ± SEM, n = 3 p <0.01). The decrease was completely blocked by co-incubation with
B6H12 (Fig 2b).
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IGF-I regulates VEGF production and receptor activation in 15 mM glucose
Previous studies have suggested that the response of cells to VEGF is regulated by IGF-I but
whether this response is altered by hyperglycemia is unknown [17,18]. In HUVECs IGF-I
stimulated a significant 2 ± 0.5 fold increase (mean ± SEM, n = 3 p<0.01) in VEGF mRNA.
This response was dependent upon the association between IAP and SHPS-1 since it was
blocked in the presence of B6H12 (Fig 3a).
To examine the significance of the increase in VEGF mRNA we examined VEGF receptor
phosphorylation in HUVECs. IGF-I stimulated a significant 12 ± 9 fold increase (mean ±
SEM n = 3 p<0.05) in VEGF R2 phosphorylation and this increase was blocked in the
presence of B6H12 (Fig 3b). To determine the significance of this increase we examined the
ability of IGF-I to stimulate a decrease in occludin in the presence of the VEGF inhibitor,
Je-11. In the presence of this inhibitor the IGF-I-stimulated decrease in occludin levels was
attenuated (Fig 3c). We observed a similar response when we examined these changes in
retinal endothelial cells grown in 15 mmol/l glucose (Fig 3d and e).
The role of IAP/SHPS-1 in vascular permeability in vivo
STZ induced hyperglycemia in rats was used to determine whether hyperglycemia induced
an increase in IAP association with SHPS-1 in vivo and whether this played a role in the
hyperglycemia-associated increase in vascular permeability
There was a 2.4 ± 0.6 fold increase in IAP/SHPS-1 association when retinal tissue from the
hyperglycemic rats was compared with normoglycemic animals [Fig 4a (mean ± SEM, n = 9
p < 0.05)]. This is somewhat less than the increase in IAP association with SHPS-1 in
cultured endothelial cells (Fig 1A and [5]) and this difference is probably due to the fact the
retinal lysates contain additional cells types compared with pure cultures of endothelial cells.
Treatment of the hyperglycemic rats with B6H12 significantly reduced IAP association with
SHPS-1 such that there was no significant difference between the B6H12 treated rats and
control treated animals (Fig 4a top panel). Consistent with our in vitro data there was a
significant increase in the amount of intact IAP in the retina from hyperglycemic rats
compared with normoglycemic, control animals. This increase in intact IAP was inhibited in
rats treated with B6H12 (Fig 4a bottom panel).
Disruption in IAP association with SHPS-1 impairs the increase in vascular permeability
associated with hyperglycemia in vivo
There was a significant, 1.7 ± 0.2 fold, increase in the permeation of Evans Blue from the
retinal vasculature of the diabetic rats compared with control (mean ± SEM, n = p<0.05).
Treatment of hyperglycemic rats with the anti-IAP antibody restored Evans Blue leakage to
a level that was comparable to that of control, normoglycemic rats (Fig 4b). We also
examined occludin levels in the normal and diabetic rats. There was a significant (p <0.05)
decrease in the amount of occludin detected in the retinal homogenates from the
hyperglycemic rats compared with control, however, this was normalized in the
hyperglycemic rats treated with B6H12 (Fig 4c).
Disruption of IAP association with SHPS-1 impairs the hyperglycemia-associated increase
in leukocyte adhesion
TNFα treatment significantly increased leukocyte adhesion to REC cultured in both 5 and
15 mmol/l glucose. However, significantly more leukocytes adhered to the REC monolayer
that had been cultured in 15mmol/l as compared cells cultured in 5 mmol/l. Pretreatment of
REC, that had been stimulated with TNFα, with B6H12 significantly decreased leukocyte
adhesion to the REC monolayer (Fig 5a).
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The number of leukocytes adhering to the retinal vasculature in the hyperglycemic rats
compared with control was increased significantly (1.4 ± 0.2 fold compared with 2.0 ± 0.3,
p<0.05). This increase was inhibited in the rats treated with B6H12 (Fig 5b) (1.2 ± 0.2 fold
increase, p, NS when compared with control).
The role of IAP/SHPS-1 in regulating tube formation
Neovascularization, which occurs in diabetes in response to hyperglycemia, requires cell
proliferation, migration and cellular fusion. We have shown previously that the
hyperglycemia induced increase in IAP/SHPS-1 is required for the increased proliferation of
retinal endothelial cells to IGF-1 [5]. To extend those observations we analyzed the role of
IAP/SHPS-1 formation in vitro tube formation in HUVEC in response to IGF-I. A
representative image and quantification of three independent experiments is shown in figure
6a. In the presence of IGF-I there was a significant (32.9 ± 2.61 fold) increase in the number
of tubes formed (mean ± SEM, n = 3) (Fig 6a). In contrast in the presence of B6H12 the
number of tubes formed was reduced significantly and not different than in the control
cultures. The ability of IGF-I to stimulate an increase in tube formation was not altered in
the presence of the VEGF inhibitor (Fig 6b).
Disruption of IAP association with SHPS-1 impairs neoangiogenesis in a rodent model of
hypoxic retinopathy
Currently, there are no rodent models of diabetes-accelerated neovascularization comparable
to that seen in human subjects with diabetes. However the rodent model of retinopathy of
prematurity (ROP) allows the opportunity to test anti-angiogenic strategies in vivo. We first
compared the level of IAP in the retinal homogenates from room-air versus ROP rat pups.
There was a significant increase in the amount of intact IAP and correspondingly a decrease
in IAP fragment in the ROP pups compared with control (Fig 6c). We then tested the ability
of B6H12 to impair the intravitreal neovascularization (IVNV) that occurs in the ROP rats.
In room air pups, retinal vascularization of the inner capillary plexus extends to the ora
serrata and there is no avascular retina or IVNV. In the ROP pups, avascular retina is 30% of
the total retinal area at p14 and 25% at p18. Approximately 4 clock hours of IVNV were
present at p18 (Fig 6d). Treatment with B6H12 markedly reduced the number of clock hours
exhibiting IVNV from (4.1 ± 0.4 to 2.0 ± 1.0 p<0.05) as well as the total IVNV area (0.6 ±
0.1 (% of total area) to 0.39 ± 0.1% p <0.05) (Fig 6d and e). There was no significant
difference in the amount of avascular area when the untreated ROP animals were compared
with the ROP treated with B6H12 (Fig 6f).
Discussion
The results of this study show that an increase in intact IAP and the increase in its
association with SHPS-1 is a generalized endothelial cell response to hypeglycemia and is
required for endothelial tube formation and increased endothelial permeability that occur in
response to IGF-I during hyperglycemia, as well as for glucose enhanced leukocyte
adherence to endothelial cells. Culturing cells in normal glucose resulted in proteolytic
cleavage of the region of IAP that contains the SHPS-1 binding site which resulted in loss of
IAP/SHPS-1 association and the ability of IGF-I to stimulate SHPS-1 phosphorylation and
downstream signaling. In contrast, exposure to 15 mmol/l glucose protected IAP from
cleavage which allowed SHPS-1/IAP association and IGF-I stimulated SHPS-1
phosphorylation. The significance of these in vitro findings is highlighted in our in vivo
studies in which we demonstrated that not only was there an increase in IAP association
with SHPS-1 in retinal homogenates from diabetic rats, but that blocking this increase
inhibited pathophysiologic changes that have been identified during the early stages of
diabetic retinopathy, for example increased endothelial permeability and leukocyte
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adherence [19,20]. These results strongly suggest that the increase in SHPS-1/IAP
association may be a critical step in the biochemical events that lead to these early changes
in the endothelium that occur in response to hyperglycemic stress.
Several studies have linked IGF-I to stimulation of diabetic retinopathy [1–4]. Endothelial
cells in culture have been shown to secrete increased amounts of IGF-I in response to
hyperglycemia [21,22]. Transgenic overexpression of IGF-I in mice has been associated
with several changes in the retina that simulate the changes that occur in diabetic retinopathy
including loss of pericytes, thickening of the capillary basement membrane and
neovascularization [4]. Administration of IGF-I to patients with diabetes has been associated
with the development of retinal edema and some evidence of increased retinopathy
progression [23]. Similarly administration of octreotide decreases IGF-I levels in vitreous
and retinopathy progression [3]. Our findings suggest inhibition of IGF-I signaling by
disrupting IAP/SHPS-1 association represents a potentially effective treatment strategy.
Our data suggest a direct, but complex relationship between IGF-I and VEGF in mediating
the changes that occur in the diabetic retina. One prior study clearly indicated that IGF-I
stimulates VEGF synthesis during angiogenesis in the retinopathy prematurity model [17].
Our data indicated that during hyperglycemic conditions IGF-I can induce VEGF synthesis
and secretion resulting in VEGF receptor activation. Whether the ability of IGF-I to
stimulate VEGF actually requires hyperglycemic stress was not addressed in these studies
but prior studies have suggested this possibility [24]. VEGF is a stimulant of angiogenesis
and inhibiting the VEGF receptor in diabetes has been shown to be antiangiogenic and to
inhibit retinal capillary leakage of proteins [25,26]. In our studies we showed that IGF-I can
support angiogenesis in a VEGF independent manner suggesting that IGF-I may contribute
to the proliferative phase of diabetic retinopathy both by direct stimulation of angiogenesis
and indirectly by increasing VEGF production. In contrast to the VEGF independent effects
of IGF-I on tube formation, the ability of IGF-I to stimulate a decrease in occludin and thus
increase vascular permeability was dependent upon VEGF mediated signaling since it was
blocked in the presence of the VEGF inhibitor.
Several junctional proteins have been linked to changes in permeability in retinal
endothelium. These include claudin-5, Z0-1, VE cadherin and occludin [27]. Occludin binds
within the tight junctions to the SH3-GUK domain of Z01 [28]. Both disassociation from the
cell border and lower concentrations of total occludin occur in diabetes [29]. Exposure to
VEGF also stimulates these changes and VE cadherin also undergoes phosphorylation and
internalization in response to VEGF stimulation [29]. The VE cadherin content is decreased
in vessels of diabetic rats and its concentration correlates inversely with vascular
permeability [30]. There is also decreased association of VE cadherin and beta catenin in
diabetic vessels. These changes are believed to be due primarily to changes in VE cadherin
and beta catenin phosphorylation [28]. Both PKC isoforms and c-Src have been shown to
phosphorylate these substrates leading to altered vascular permeability. Src phosphorylation
of occludin leads to its disassociation from the adherens complex and its degradation [30].
VEGF has been shown to stimulate Src dependent occludin phosphorylation and Src can
also phosphorylate Z0-1 leading to changes in its localization [31]. Since IGF-I stimulated
SHPS-1 phosphorylation in VSMC enhances Src activation this represents a potential
mechanism leading to occludin downregulation in response to hyperglycemia [32,33].
Future studies will be required to determine whether stimulation of IGF-I signaling has
direct effects on the localization of VE cadherin, beta catenin or other components of
endothelial cell tight junctions and/or an effect mediated through its regulation of VEGF
signaling.
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The translational impact of these observations is hard to predict. The length of time that the
rodents were diabetic is very short compared with the length of time that diabetic
retinopathy develops in humans. While the severity of retinopathy in animal models
increases with duration of diabetes it remains mild compared with that seen in many patients
with diabetes. Additionally, our studies focused on endothelial cells but the development of
diabetic retinopathy includes changes in other cell types such as pericytes and retinal
pigmented epithelial cells.
Despite these limitations, taken together with our other recent study [5], our data provides
evidence that the hyperglycemia induced increase in IAP/SHPS-1 is a generalized response
of endothelial cells and it contributes to changes in endothelial cell function, furthermore,
our data suggest that this novel biochemical pathway may contribute to the early changes in
vascular cell function that occur in diabetes including diabetic retinopathy.
Acknowledgments
This work was supported by a grant from the Juvenile Diabetes Research Foundation (17-2008-1048). The authors
wish to thank Ms. Laura Lindsey for her help in preparing the manuscript.
Abbreviations
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Figure 1. Glucose regulation of IAP cleavage and IAP association with SHPS-1
HUVECs and RECs were grown to confluency in either 15 of 5 mmol/l glucose prior to
overnight incubation in serum free medium with the appropriate glucose concentration.
a. IAP association with SHPS-1 was determined by immunoprecipitating (IP) HUVEC
lysates using an anti-SHPS-1 antibody then immunoblotting (IB) with an IAP antibody
(B6H12). Equal amounts of protein were separated by SDS-PAGE and immunoblotted with
the anti-SHPS-1 antibody to demonstrate that the different in IAP association with SHPS-1
is not due to difference in SHPS-1 levels.
b. Cell lysates were obtained from HUVECs that had exposed to IGF-I (50 ng/ml) for 5 min.
The lysates were immunoprecipitated with an anti-SHPS-1 antibody and immunoblotted for
phosphotyrosine (p-Tyr). To control for loading an equal amount of lysate was
immunoblotted for SHPS-1. Bands shown are from discontinuous lanes of the same gel.
c. To examine IAP cleavage equal amounts of HUVEC (HU) and REC (REC) lysate were
separated by SDS-PAGE and immunoblotted with the anti-IAP antibody B6H12 that
recognizes both intact and fragments of IAP.
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Figure 2. The association between IAP and SHPS-1 is required for IGF-I stimulated cell
permeability
a: HUVECs plated on transwell inserts were treated with either IGF-I (50ng/ml) or IGF-I +
B6H12 (1 μg/ml) overnight prior to exposure to fluorescently labeled dextran. The graph
shows the mean fold increase in dextran permeation through the membrane (mean ± SEM n
= 3, **p <0.01 when the amount of dextran that permeated in the presence of IGF-I is
compared with either control or IGF-I + B6H12).
b & c: Occludin protein levels were determined by immunoblotting equal amounts of protein
from HUVECs (b) and RECs (c) treated as described for fig 2a. To determine that the
difference in occludin levels was not due to a different in total protein the lysates were also
immunoblotted with an anti-β3 antibody. Bands shown are from discontinuous lanes of the
same gel
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Figure 3. IGF-I regulates VEGF
a: RNA was prepared from whole cell lysates. One microgram of total RNA was reverse
transcribed. Two ul of cDNA was used in each RT-PCR reaction. A standard curve was
generated using the control sample (10 fold dilutions from 1 to 10,000). The graph shows
the results of three independent experiments (mean ± SEM, n = 3, *p<0.01 when the amount
of VEGF mRNA in the presence of IGF-I is compared with either control or IGF-I +
B6H12).
b: HUVECs were grown to confluency in medium containing 15 mmol/l glucose prior to
overnight incubation in serum free medium with the same glucose concentration plus IGF-I
(50 ng/ml) with or without the addition of B6H12 (1 μg/ml). The extent of VEGFR2
phosphorylation was determined by immunoprecipitating with an anti-phosphotyrosine
antibody (p-Tyr) and immunoblotting with an anti-VEGFR2 antibody. To control for
differences in protein, cell lysates were also immunoblotted directly with the anti-VEGFR2
antibody. The graph shows the results of 3 independent experiments expressed as arbitrary
scanning units (mean ± SEM, n =3 *p<0.05 when the extent of VEGFR2 phosphorylation in
the presence of IGF-I is compared with control or IGF-I + B6H12).
c: HUVECs were grown to confluency in medium containing 15 mmol/l glucose prior to
overnight incubation in serum free medium with the same glucose concentration plus IGF-I
(50ng/ml) with or without the addition of the VEGF inhibitor (VEGFi) Je-11 (10 μg/ml).
Equal amounts of cell lysates were separated by SDS-PAGE and the amount of occludin
was assessed by immunoblotting. ***p<0.05 when the change in occludin in response to
IGF-I was compared to control or IGF-I + VEGFi.
d and e: REC were grown to confluency and treated as for 3b and c. Bands shown are from
discontinuous lanes of the same gel. Control and IGF-I treated results are the same as those
shown in figure 2b.
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Figure 4. B6H12 disrupts IAP association with SHPS-1 in vivo thereby inhibiting diabetes
increased vascular permeability
a: Individual retinal lysates from control (CON), diabetic and diabetic rats treated with
B6H12 (+B6H12) were immunoprecipitated with an anti-SHPS-1 antibody and
immunoblotted with an anti-IAP antibody (upper panel) or the lysates were immunoblotted
directly with an anti-IAP antibody, R569, that selectively recognizes only intact IAP
(bottom panel). The graph shows the association of IAP with SHPS-1 expressed as arbitrary
scanning units (mean ± SEM, n = 9, *p<0.05 when diabetic rats are compared with either
control or diabetic rats treated with B6H12.
b: Evans Blue permeation from the retinal vasculature was measured by spectrophotometry
and corrected for plasma concentration, retina weight and time. The graph shows the mean
amount of Evans Blue harvested from retina from each group of rats (mean ± SEM) (n = 37,
con nondiabetic) (n=21, diabetic treated with control IgG) and (n=23, diabetic treated with
B6H12). The permeation of Evans Blue from the diabetic retinal vasculature was
significantly increased compared with control or diabetic treated with B6H12 (*p<0.05).
c: Individual retinal lysates from nondiabetic, control and diabetic rats treated control IgG,
or B6H12 (+B6H12) were immunoblotted directly using an anti-occludin antibody. The
graph shows the data expressed as arbitrary scanning units (mean ± SEM, n = 9, *p <0.05
when occluding levels in retina from diabetic animals treated with IgG were compared with
either control, nondiabetic or diabetic animals treated with B6H12.
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Figure 5. Disruption in IAP association with SHPS-1 disrupts leukocyte adhesion to endothelial
cells in hyperglycemic conditions
a: The number of fluorescently labeled leukocytes adhering to a confluent monolayer of
retinal endothelial cells in 5 mmol/l (NG) or 15mmol/l (HG) glucose, in the presence (+) or
absence (−) of TNFα with (+) or without B6H12 (1 μg/ml) was assessed (mean ± SEM n =
3 **p <0.01 when leukocyte adhesion in the presence of TNFα is compared with adhesion
in its absence irrespective of the glucose culture conditions, * p<0.05 when leukocyte
adhesion in HG + TNFα the presence of B6H12 is compared with its absence).
b: Leukocyte adhesion to the retinal vasculature assessed and expressed as the number of
leukocytes/107 pixels. The graph shows the mean ± SEM n = 14 (con) n=22 (diabetic) n=17
(diabetic + B6H12 treatment) *p<0.05 when diabetic rats treated with IgG are compared to
nondiabetic or diabetic rats who received B6H12.
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Figure 6. Disruption of IAP association with SHPS-1 impairs IVNV in a rodent model of
retinopathy of prematurity
a&b: HUVECs were plated on growth factor-reduced matrigel in the presence of IGF-I
(50ng/ml) and/or B6H12 (1μg/ml) and/or VEGF inhibitor (10 μg/ml). Tube formation was
allowed to proceed for 4 hours at which point photographs were taken at 10x magnification.
Tube number was quantified. The graph shows the mean number of tubes formed from 3
independent experiments (mean ± SEM, n = 3 *p<0.05 when the number of tubes in the
presence of IGF-I is compared with the number of tubes formed in SFM alone or in the
presence of IGF-I + B6H12).
c: Pools of retinal lysates from room air (RA) and ROP rat pups were immunoblotted with
an anti-IAP antibody that specifically recognizes intact IAP R569 (upper panel) or with an
anti-IAP antibody B6H12 that specifically recognizes both intact and fragmented IAP
(middle panel). An actin immunoblot is shown as a loading control (bottom panel).
d, e and f. Lectin-stained retinal flat mounts from pups injected at p12 with (B6H12) or
control IgG (con)were analyzed at day 18. The total IVNV area is shown in (d) the number
of clock hours of intravitreous neovascularization (IVNV) is shown in (e), and avascular
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area in (f). *p<0.05 when control (con) is compared to B6H12. Representative images are
shown in figure 6g.
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Table 1
Characteristics of the STZ hyperglycemic rat model
Rat Group Weight (g)a Glucose levels mmol/l Duration of diabetes
Control 333 ± 23 8.14 ± 0.5 -
Diabetic 306 ± 7 25 ± 0.9* 50 days
Diabetic + B6H12 276 ± 7 23.2 ± 0.95* 50 days
a
the rate of weight gain was attenuated in the diabetic group but no rat lost weight data shown is mean ± SEM n >20
*
p < 0.05 when compared with control group
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